APA

Yang S. C., Grimm E. A., Parkinson D. R., Carinhas J., Fry K. D., Mendiguren-Rodriguez A., Licciardello J., Owen-Schaub L. B., Hong W. K. & Roth J. A. (19910812). Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. : Cancer research.

Chicago

Yang S C, Grimm E A, Parkinson D R, Carinhas J, Fry K D, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub L B, Hong W K and Roth J A. 19910812. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. : Cancer research.

Harvard

Yang S. C., Grimm E. A., Parkinson D. R., Carinhas J., Fry K. D., Mendiguren-Rodriguez A., Licciardello J., Owen-Schaub L. B., Hong W. K. and Roth J. A. (19910812). Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. : Cancer research.

MLA

Yang S C, Grimm E A, Parkinson D R, Carinhas J, Fry K D, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub L B, Hong W K and Roth J A. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. : Cancer research. 19910812.